← Back to Search

Alkylating agents

Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide for Central Nervous System Lymphoma (PCNSL Trial)

Phase 2
Waitlist Available
Led By Christian Grommes, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

PCNSL Trial Summary

This trial is testing a new cancer treatment to see if it is safe and effective. The current standard treatment for this cancer only cures less than half of patients, and often has serious side effects.

Eligible Conditions
  • Central Nervous System Lymphoma
  • Brain Cancer
  • Non-Hodgkin's Lymphoma

PCNSL Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants Evaluated for Toxicity
Secondary outcome measures
Overall Response Rates

Side effects data

From 2023 Phase 2 trial • 33 Patients • NCT00596154
33%
Fatigue
21%
Death not related to disease
21%
Neuropathy: sensory
15%
Constipation
12%
Neuropathy: motor
9%
ALT, SGPT
9%
Nausea
9%
Infection, other
9%
Thrombosis/thrombus/embolism
9%
AST, SGOT
6%
Dysgeusia
6%
Rash: erythema multiforme
6%
Rash/desquamation
6%
Lymphopenia
6%
Pain - Head/headache
6%
Vomiting
6%
Diarrhea
3%
Ophthalmoplegia/diplopia (double vision)
3%
Obstruction, GI- Small bowel NOS
3%
Confusion
3%
Pain - Chest/thorax NOS
3%
Seizure
3%
Liver dysfunction/failure
3%
Fever (in the absence of neutropenia)
3%
Creatinine
3%
Osteonecrosis (avascular necrosis)
100%
80%
60%
40%
20%
0%
Study treatment Arm
Newly Diagnosed Primary CBS Lymphoma/PCNSL

PCNSL Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
Rituximab, methotrexate (MTX), procarbazine and vincristine (R-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed at the discretion of the hematology attending (usually after the 1st or 2nd cycle of R-MPV)and high dose chemotherapy Busulfan, Thiotepa, and Cyclophosphamide. Patients will be off study at the time of death. All patients will be followed for survival every 6 months throughout their lifetime. Survival status may be obtained by phone call, clinical visit or medical records (e.g. physician notes/laboratory results of clinic or hospital visit.

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,935 Previous Clinical Trials
588,822 Total Patients Enrolled
3 Trials studying Central Nervous System Lymphoma
128 Patients Enrolled for Central Nervous System Lymphoma
Christian Grommes, MDPrincipal InvestigatorMemorial SloanKettering Cancer Center
6 Previous Clinical Trials
209 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
BloodJournal
R-MPV Followed by High-dose Chemotherapy with TBC and Autologous Stem-cell Transplant for Newly Diagnosed Primary CNS Lymphoma
Omuro, Antonio, Denise D. Correa, Lisa M. DeAngelis, Craig H. Moskowitz, Matthew J. Matasar, Thomas J. Kaley, Igor T. Gavrilovic, et al.. 2015. “R-MPV Followed by High-dose Chemotherapy with TBC and Autologous Stem-cell Transplant for Newly Diagnosed Primary CNS Lymphoma”. Blood. American Society of Hematology. doi:10.1182/blood-2014-10-604561.
clinicaltrials.govStudy
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma
2004. "Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00596154.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top